Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells

Figure 3

Th17 cell percentages differ among different karyotype groups. Differences of Th17 percentages between normal and abnormal karyotype groups were shown (a-b). PB and BM Th17 percentages in MDS patients with good, intermediate, and poor karyotypes were shown in (c) and (d).

(a)

(b)

(c)

(d)